June 1 (Reuters) - Switzerland's AC Immune, which already
has money in hand from Roche for its most advanced drug,
is planning a share sale in the United States to raise up to $50
million for separate drug candidates targeting Alzheimer's
disease.
Read more
No comments:
Post a Comment